Prophylactic Interventions for Hereditary Breast and Ovarian Cancer Risks and Mortality in BRCA1/2 Carriers
Abstract
:Simple Summary
Abstract
1. Introduction
2. Methods
2.1. Search Strategy and Inclusion Criteria
2.2. Data Extraction
2.3. Risk of Bias Assessment
2.4. Data Synthesis and Analysis
3. Results
3.1. Narrative Synthesis
3.2. Meta-Analysis Results
3.3. Subgroup Analysis
3.4. Quality Assessment
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Data Availability Statement
Conflicts of Interest
References
- American Cancer Society. Breast Cancer Statistics|How Common Is Breast Cancer; American Cancer Society: Atlanta, GA, USA, 2023. [Google Scholar]
- American Cancer Society. Ovarian Cancer Statistics|How Common is Ovarian Cancer; American Cancer Society: Atlanta, GA, USA, 2023. [Google Scholar]
- WCRF International. Ovarian Cancer Statistics|World Cancer Research Fund International; WCRF International: London, UK, 2022. [Google Scholar]
- Ford, D.; Easton, D.; Stratton, M.; Narod, S.; Goldgar, D.; Devilee, P.; Bishop, D.; Weber, B.; Lenoir, G.; Chang-Claude, J. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am. J. Hum. Genet. 1998, 62, 676–689. [Google Scholar] [CrossRef] [PubMed]
- King, M.-C.; Marks, J.H.; Mandell, J.B. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003, 302, 643–646. [Google Scholar] [CrossRef] [PubMed]
- Struewing, J.P.; Hartge, P.; Wacholder, S.; Baker, S.M.; Berlin, M.; McAdams, M.; Timmerman, M.M.; Brody, L.C.; Tucker, M.A. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N. Engl. J. Med. 1997, 336, 1401–1408. [Google Scholar] [CrossRef] [PubMed]
- Antoniou, A.; Pharoah, P.D.; Narod, S.; Risch, H.A.; Eyfjord, J.E.; Hopper, J.L.; Loman, N.; Olsson, H.; Johannsson, O.; Borg, Å. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am. J. Hum. Genet. 2003, 72, 1117–1130. [Google Scholar] [CrossRef]
- Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br. J. Cancer 2000, 83, 1301. [Google Scholar] [CrossRef] [PubMed]
- Satagopan, J.M.; Boyd, J.; Kauff, N.D.; Robson, M.; Scheuer, L.; Narod, S.; Offit, K. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin. Cancer Res. 2002, 8, 3776–3781. [Google Scholar] [PubMed]
- Domchek, S.M.; Friebel, T.M.; Singer, C.F.; Evans, D.G.; Lynch, H.T.; Isaacs, C.; Garber, J.E.; Neuhausen, S.L.; Matloff, E.; Eeles, R. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010, 304, 967–975. [Google Scholar] [CrossRef]
- Metcalfe, K.; Eisen, A.; Senter, L.; Armel, S.; Bordeleau, L.; Meschino, W.S.; Pal, T.; Lynch, H.T.; Tung, N.M.; Kwong, A. International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. Br. J. Cancer 2019, 121, 15–21. [Google Scholar] [CrossRef]
- Kotsopoulos, J.; Gronwald, J.; Huzarski, T.; Aeilts, A.; Randall Armel, S.; Karlan, B.; Singer, C.F.; Eisen, A.; Tung, N.; Olopade, O. Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation. Breast Cancer Res. Treat. 2023, 201, 257–264. [Google Scholar] [CrossRef]
- American Cancer Society. Cochrane Handbook for Systematic Reviews of Interventions; American Cancer Society: Atlanta, GA, USA, 2023. [Google Scholar]
- Wells, G.A.; Shea, B.; O’Connell, D.; Peterson, J.; Welch, V.; Losos, M.; Tugwell, P. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Ottawa Hospital Research Institute. Ohrica. 2021. Available online: https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed on 20 December 2023).
- Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G.; Group, P. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Int. J. Surg. 2010, 8, 336–341. [Google Scholar] [CrossRef]
- Domchek, S.M.; Friebel, T.M.; Neuhausen, S.L.; Wagner, T.; Evans, G.; Isaacs, C.; Garber, J.E.; Daly, M.B.; Eeles, R.; Matloff, E. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: A prospective cohort study. Lancet Oncol. 2006, 7, 223–229. [Google Scholar] [CrossRef] [PubMed]
- Eisen, A.; Lubinski, J.; Klijn, J.; Moller, P.; Lynch, H.T.; Offit, K.; Weber, B.; Rebbeck, T.; Neuhausen, S.L.; Ghadirian, P. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: An international case-control study. J. Clin. Oncol. 2005, 23, 7491–7496. [Google Scholar] [CrossRef] [PubMed]
- Finch, A.; Beiner, M.; Lubinski, J.; Lynch, H.T.; Moller, P.; Rosen, B.; Murphy, J.; Ghadirian, P.; Friedman, E.; Foulkes, W.D. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 2006, 296, 185–192. [Google Scholar] [CrossRef]
- Finch, A.P.; Lubinski, J.; Møller, P.; Singer, C.F.; Karlan, B.; Senter, L.; Rosen, B.; Maehle, L.; Ghadirian, P.; Cybulski, C. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J. Clin. Oncol. 2014, 32, 1547. [Google Scholar] [CrossRef] [PubMed]
- Heemskerk-Gerritsen, B.; Menke-Pluijmers, M.; Jager, A.; Tilanus-Linthorst, M.; Koppert, L.; Obdeijn, I.; Van Deurzen, C.; Collée, J.; Seynaeve, C.; Hooning, M. Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: A prospective analysis. Ann. Oncol. 2013, 24, 2029–2035. [Google Scholar] [CrossRef]
- Heemskerk-Gerritsen, B.A.; Jager, A.; Koppert, L.B.; Obdeijn, A.I.-M.; Collée, M.; Meijers-Heijboer, H.E.; Jenner, D.J.; Oldenburg, H.S.; van Engelen, K.; de Vries, J. Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. Treat. 2019, 177, 723–733. [Google Scholar] [CrossRef]
- Ingham, S.L.; Sperrin, M.; Baildam, A.; Ross, G.L.; Clayton, R.; Lalloo, F.; Buchan, I.; Howell, A.; Evans, D.G.R. Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral. Breast Cancer Res. Treat. 2013, 142, 611–618. [Google Scholar] [CrossRef]
- Kaas, R.; Verhoef, S.; Wesseling, J.; Rookus, M.A.; Oldenburg, H.S.; Peeters, M.-J.V.; Rutgers, E.J. Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: Very low risk for subsequent breast cancer. Ann. Surg. 2010, 251, 488–492. [Google Scholar] [CrossRef]
- Kauff, N.D.; Satagopan, J.M.; Robson, M.E.; Scheuer, L.; Hensley, M.; Hudis, C.A.; Ellis, N.A.; Boyd, J.; Borgen, P.I.; Barakat, R.R. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 2002, 346, 1609–1615. [Google Scholar] [CrossRef]
- Kauff, N.D.; Domchek, S.M.; Friebel, T.M.; Robson, M.E.; Lee, J.; Garber, J.E.; Isaacs, C.; Evans, D.G.; Lynch, H.; Eeles, R.A. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1-and BRCA2-associated breast and gynecologic cancer: A multicenter, prospective study. J. Clin. Oncol. 2008, 26, 1331. [Google Scholar] [CrossRef]
- King, M.-C.; Wieand, S.; Hale, K.; Lee, M.; Walsh, T.; Owens, K.; Tait, J.; Ford, L.; Dunn, B.K.; Costantino, J. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001, 286, 2251–2256. [Google Scholar] [CrossRef] [PubMed]
- Kotsopoulos, J.; Olopade, O.I.; Ghadirian, P.; Lubinski, J.; Lynch, H.T.; Isaacs, C.; Weber, B.; Kim-Sing, C.; Ainsworth, P.; Foulkes, W.D. Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2005, 7, 1–11. [Google Scholar] [CrossRef] [PubMed]
- Kotsopoulos, J.; Huzarski, T.; Gronwald, J.; Singer, C.F.; Moller, P.; Lynch, H.T.; Armel, S.; Karlan, B.; Foulkes, W.D.; Neuhausen, S.L. Bilateral oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers. J. Natl. Cancer Inst. 2017, 109, djw177. [Google Scholar] [CrossRef]
- Mavaddat, N.; Antoniou, A.C.; Mooij, T.M.; Hooning, M.J.; Heemskerk-Gerritsen, B.A.; Noguès, C.; Gauthier-Villars, M.; Caron, O.; Gesta, P. Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: An international prospective cohort of BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2020, 22, 8. [Google Scholar] [CrossRef] [PubMed]
- Meijers-Heijboer, H.; van Geel, B.; van Putten, W.L.; Henzen-Logmans, S.C.; Seynaeve, C.; Menke-Pluymers, M.B.; Bartels, C.C.; Verhoog, L.C.; van den Ouweland, A.M.; Niermeijer, M.F. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 2001, 345, 159–164. [Google Scholar] [CrossRef] [PubMed]
- Rebbeck, T.R.; Lynch, H.T.; Neuhausen, S.L.; Narod, S.A.; Van’t Veer, L.; Garber, J.E.; Evans, G.; Isaacs, C.; Daly, M.B.; Matloff, E. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 2002, 346, 1616–1622. [Google Scholar] [CrossRef]
- Rebbeck, T.R.; Friebel, T.; Lynch, H.T.; Neuhausen, S.L.; Van’t Veer, L.; Garber, J.E.; Evans, G.R.; Narod, S.A.; Isaacs, C.; Matloff, E. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group. J. Clin. Oncol. 2004, 22, 1055–1062. [Google Scholar] [CrossRef]
- Rutter, J.L.; Wacholder, S.; Chetrit, A.; Lubin, F.; Menczer, J.; Ebbers, S.; Tucker, M.A.; Struewing, J.P.; Hartge, P. Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: An Israeli population-based case–control study. J. Natl. Cancer Inst. 2003, 95, 1072–1078. [Google Scholar] [CrossRef]
- Skytte, A.B.; Crüger, D.; Gerster, M.; Lænkholm, A.V.; Lang, C.; Brøndum-Nielsen, K.; Andersen, M.; Sunde, L.; Kølvraa, S.; Gerdes, A.M. Breast cancer after bilateral risk-reducing mastectomy. Clin. Genet. 2011, 79, 431–437. [Google Scholar] [CrossRef]
- D’Alonzo, M.; Piva, E.; Pecchio, S.; Liberale, V.; Modaffari, P.; Ponzone, R.; Biglia, N. Satisfaction and impact on quality of life of clinical and instrumental surveillance and prophylactic surgery in BRCA-mutation carriers. Clin. Breast Cancer 2018, 18, e1361–e1366. [Google Scholar] [CrossRef]
- Abul-Husn, N.S.; Soper, E.R.; Odgis, J.A.; Cullina, S.; Bobo, D.; Moscati, A.; Rodriguez, J.E.; Team, C.G.; Center, R.G.; Loos, R.J. Exome sequencing reveals a high prevalence of BRCA1 and BRCA2 founder variants in a diverse population-based biobank. Genome Med. 2020, 12, 2. [Google Scholar] [CrossRef] [PubMed]
- Petrucelli, N.; Daly, M.B.; Pal, T. BRCA1-and BRCA2-Associated Hereditary Breast and Ovarian Cancer; University of Washington: Seattle, WA, USA, 2022. [Google Scholar]
- Chéreau, E.; Uzan, C.; Balleyguier, C.; Chevalier, J.; de Paillerets, B.B.; Caron, O.; Rimareix, F.; Mathieu, M.-C.; Koskas, M.; Bourgier, C. Characteristics, treatment, and outcome of breast cancers diagnosed in BRCA1 and BRCA2 gene mutation carriers in intensive screening programs including magnetic resonance imaging. Clin. Breast Cancer 2010, 10, 113–118. [Google Scholar] [CrossRef] [PubMed]
- NCCN. Guidelines Detail; NCCN: Plymouth Meeting, PA, USA, 2023. [Google Scholar]
- Grann, V.R.; Patel, P.R.; Jacobson, J.S.; Warner, E.; Heitjan, D.F.; Ashby-Thompson, M.; Hershman, D.L.; Neugut, A.I. Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers. Breast Cancer Res. Treat. 2011, 125, 837–847. [Google Scholar] [CrossRef] [PubMed]
- Manna, E.D.F.; Serrano, D.; Aurilio, G.; Bonanni, B.; Lazzeroni, M. Chemoprevention and Lifestyle Modifications for Risk Reduction in Sporadic and Hereditary Breast Cancer. Healthcare 2023, 11, 2360. [Google Scholar] [CrossRef] [PubMed]
- Piek, J.M.; Verheijen, R.H.; Kenemans, P.; Massuger, L.F.; Bulten, H.; Van Diest, P.J. BRCA1/2-related ovarian cancers are of tubal origin: A hypothesis. Gynecol. Oncol. 2003, 90, 491. [Google Scholar] [CrossRef] [PubMed]
- Neff, R.T.; Senter, L.; Salani, R. BRCA mutation in ovarian cancer: Testing, implications and treatment considerations. Ther. Adv. Med. Oncol. 2017, 9, 519–531. [Google Scholar] [CrossRef] [PubMed]
- Manchanda, R.; Gaba, F.; Talaulikar, V.; Pundir, J.; Gessler, S.; Davies, M.; Menon, U.; on behalf of the Royal College of Obstetricians and Gynaecologists. Risk-reducing salpingo-oophorectomy and the use of hormone replacement therapy below the age of natural menopause: Scientific impact paper No. 66. BJOG Int. J. Obstet. Gynaecol. 2022, 129, e16–e34. [Google Scholar] [CrossRef]
- Erekson, E.A.; Martin, D.K.; Ratner, E.S. Oophorectomy: The debate between ovarian conservation and elective oophorectomy. Menopause 2013, 20, 110. [Google Scholar] [CrossRef]
- Shu, C.A.; Pike, M.C.; Jotwani, A.R.; Friebel, T.M.; Soslow, R.A.; Levine, D.A.; Nathanson, K.L.; Konner, J.A.; Arnold, A.G.; Bogomolniy, F. Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations. JAMA Oncol. 2016, 2, 1434–1440. [Google Scholar] [CrossRef]
- Jiang, S.; Wang, Y.; Zhou, J.; Jiang, Y.; Liu, G.G.; Wu, J. Incorporating future unrelated medical costs in cost-effectiveness analysis in China. BMJ Glob. Health 2021, 6, e006655. [Google Scholar] [CrossRef]
- Jiang, S.; Wang, Y.; Si, L.; Zang, X.; Gu, Y.-Y.; Jiang, Y.; Liu, G.G.; Wu, J. Incorporating productivity loss in health economic evaluations: A review of guidelines and practices worldwide for research agenda in China. BMJ Glob. Health 2022, 7, e009777. [Google Scholar] [CrossRef] [PubMed]
- Jiang, S.; Chen, Z.; Wu, J.; Zang, X.; Jiang, Y. Addressing methodological and ethical issues in practicing health economic evaluation in China. J. Glob. Health 2020, 10, 020322. [Google Scholar] [CrossRef] [PubMed]
- Tappenden, P.; Chilcott, J.; Brennan, A.; Squires, H.; Stevenson, M. Whole Disease Modeling to Inform Resource Allocation Decisions in Cancer: A Methodological Framework. Value Health 2012, 15, 1127–1136. [Google Scholar] [CrossRef] [PubMed]
- Jiang, S.; Ren, R.; Gu, Y.; Jeet, V.; Liu, P.; Li, S. Patient Preferences in Targeted Pharmacotherapy for Cancers: A Systematic Review of Discrete Choice Experiments. Pharmacoeconomics 2022, 41, 43–57. [Google Scholar] [CrossRef] [PubMed]
- Gasparri, M.L.; Taghavi, K.; Fiacco, E.; Zuber, V.; Di Micco, R.; Gazzetta, G.; Valentini, A.; Mueller, M.D.; Papadia, A.; Gentilini, O.D. Risk-reducing bilateral salpingo-oophorectomy for BRCA mutation carriers and hormonal replacement therapy: If it should rain, better a drizzle than a storm. Medicina 2019, 55, 415. [Google Scholar] [CrossRef]
- Simões Corrêa Galendi, J.; Kautz-Freimuth, S.; Stock, S.; Müller, D. Uptake rates of risk-reducing surgeries for women at increased risk of hereditary breast and ovarian Cancer applied to cost-effectiveness analyses: A scoping systematic review. Cancers 2022, 14, 1786. [Google Scholar] [CrossRef]
- Jiang, J.; Jiang, S.; Ahumada-Canale, A.; Chen, Z.; Si, L.; Jiang, Y.; Yang, L.; Gu, Y. Breast Cancer Screening Should Embrace Precision Medicine: Evidence by Reviewing Economic Evaluations in China. Adv. Ther. 2023, 40, 1393–1417. [Google Scholar] [CrossRef]
Study | Study Country | Study Purpose | Study Design | Participants | Sample Size | Intervention | Outcomes |
---|---|---|---|---|---|---|---|
Domchek et al. (2006) [16] | US and Europe | Estimating overall mortality or BRCA-related gynecologic cancer-specific mortality reduction after BPSO | Prospective cohort study | Women with BRCA1 or BRCA2 mutations | 426 for primary analysis, 666 for secondary analysis | BPSO | HR for cancer risk and mortality |
Domchek et al. (2010) [10] | North America and Europe | Estimating BC- and OC-specific risk and mortality reduction after RRM and RRSO | Prospective cohort study | Women with BRCA1 or BRCA2 mutations | 2482 | RRM. RRSO | HR for cancer risk and mortality |
Eisen et al. (2005) [17] | North America, Europe, and Israel | Estimating BC-specific risk reduction after PO | Case–control study | Patients with breast cancer and matched controls with BRCA mutations | 1439 patients, 1866 controls | PO | OR for cancer risk |
Finch et al. (2006) [18] | Canada, US, Europe, and Israel | Estimating OC-and other BRCA-related gynecologic cancer-specific risk reduction after BPSO | Prospective cohort study | Women with BRCA1 or BRCA2 mutations | 1828 | BPSO | Incidence rate and HR for cancer risk |
Finch et al. (2014) [19] | Canada, US, Austria, France, Italy, Norway, Poland | Estimating OC- and other BRCA-related gynecologic cancer-specific risk and all-cause mortality reduction after PO | Prospective cohort study | Women with BRCA1 or BRCA2 mutations | 5783 | PO | HR for cancer risk and mortality |
Heemskerk- Gerritsen et al. (2013) [20] | Netherlands | Estimating BC-specific risk and mortality reduction after BRRM | Prospective cohort study | Women with BRCA1 or BRCA2 mutations | 570 | BRRM | Incidence rate for cancer risk and HR for mortality |
Heemskerk- Gerritsen et al. (2019) [21] | Netherlands | Estimating BC-specific mortality reduction after BRRM | Prospective cohort study | Women with BRCA1 or BRCA2 mutations | 2857 | BRRM | HR for mortality |
Ingham et al. (2013) [22] | UK | Estimating BC- and OC-specific mortality reduction after BRRM and BRRSO | Prospective cohort study | Women with BRCA1 or BRCA2 mutations | 691 | BRRSO | HR for mortality |
Kaas et al. (2010) [23] | Netherlands | Estimating BC-specific risk reduction after BRRM | Prospective cohort study | Women with BRCA1 or BRCA2 mutations | 254 | BRRM | Incidence rate for cancer risk |
Kauff et al. (2002) [24] | US | Estimating BC- and OC- and other BRCA-related gynecologic cancer-specific risk reduction after RRSO | Prospective cohort study | Women with BRCA1 or BRCA2 mutations, 35 years of age or older | 265 | RRSO | HR for cancer risk |
Kauff et al. (2008) [25] | US | Estimating BC- and other BRCA-related gynecologic cancer-specific risk reduction after RRSO | Prospective cohort study | Women with BRCA1 or BRCA2 mutations, 30 years of age or older | 1079 | RRSO | HR for cancer risk |
King et al. (2001) [26] | US | Estimating BC-specific risk reduction after chemoprevention of tamoxifen | Randomized controlled trial | Women with BRCA1 or BRCA2 mutations, 35 years of age or older with a 1.66% risk of BC over the next 5 years | 13,195 | Tamoxifen | RR for cancer risk |
Kotsopoulos et al. (2005) [27] | Canada, Israel, UK, Poland, US | Estimating BC-specific risk reduction after a change in body weight | Case–control study | Women with BRCA1 or BRCA2 mutations | 1073 patients, 1073 controls | Body weight change | OR for cancer risk |
Kotsopoulos et al. (2017) [28] | 12 countries including Canada and the US | Estimating BC-specific risk reduction after BO | Prospective cohort study | Women with BRCA1 or BRCA2 mutations | 3722 | BO | HR and adjusted HR for cancer risk |
Kotsopoulos et al. (2023) [12] | 17 countries including Canada and the US | Estimating BC-specific risk reduction after chemoprevention of tamoxifen | Prospective cohort study | Women with BRCA1 or BRCA2 mutations | 4578 | Tamoxifen | HR for cancer risk |
Mavaddat et al. (2020) [29] | UK | Estimating BC-specific risk reduction after RRSO | Prospective cohort study | Women with BRCA1 or BRCA2 mutations | 3877 | RRSO | HR for cancer risk |
Meijers- Heijboer et al. (2001) [30] | Netherlands | Estimating BC-specific risk reduction after BRRM | Prospective cohort study | Women with BRCA1 or BRCA2 mutations | 139 | BRRM | HR for cancer risk |
Rebbeck et al. (2002) [31] | North America, Europe | Estimating BC- and OC-specific risk reduction after PO | Prospective cohort study | Women with BRCA1 or BRCA2 mutations | 551 | PO | HR for cancer risk |
Rebbeck et al. (2004) [32] | North America, Europe | Estimating BC-specific risk reduction after BPM | Case–control study | Women with BRCA1 or BRCA2 mutations | 105 patients, 378 controls | BPM | Adjusted HR for cancer risk |
Rutter et al. (2003) [33] | Israel | Estimating OC-specific risk reduction after BRCA-related gynecologic surgeries | Case–control study | Jewish women confirmed with epithelial ovarian cancer or primary peritoneal cancer | 1124 patients, 2396 controls | BO, gynecologic surgeries with or without ovarian tissue removed | OR for cancer risk |
Skytte et al. (2011) [34] | Denmark | Estimating BC-specific risk reduction after BRRM | Prospective cohort study | Women with BRCA1 or BRCA2 mutations | 307 | BRRM | Incidence rate for cancer risk |
Study and Publication Years | Selection | Comparability | Exposure/Outcome | Score | |||||
---|---|---|---|---|---|---|---|---|---|
Domchek et al., 2006 [16] | * | * | * | * | ** | * | * | * | 9 |
Domchek et al., 2010 [10] | * | * | * | ** | * | * | * | 8 | |
Eisen et al., 2005 [17] | * | * | * | * | * | * | * | 7 | |
Finch et al., 2006 [18] | * | * | * | * | ** | * | * | * | 9 |
Finch et al., 2014 [19] | * | * | * | * | * | * | * | 7 | |
Heemskerk-Gerritsen et al., 2013 [20] | * | * | * | * | ** | * | * | 8 | |
Heemskerk-Gerritsen et al., 2019 [21] | * | * | * | * | ** | * | * | * | 9 |
Ingham et al., 2013 [22] | * | * | * | * | * | * | * | 7 | |
Kaas et al., 2010 [23] | * | * | * | * | * | * | * | 7 | |
Kauff et al., 2002 [24] | * | * | ** | * | * | * | 7 | ||
Kauff et al., 2008 [25] | * | * | * | ** | * | * | * | 8 | |
Kotsopoulos et al., 2005 [27] | * | * | * | * | ** | * | 7 | ||
Kotsopoulos et al., 2017 [28] | * | * | * | * | ** | * | * | * | 9 |
Kotsopoulos et al., 2023 [12] | * | * | * | * | ** | * | 7 | ||
Mavaddat et al., 2020 [29] | * | * | * | * | * | * | * | * | 8 |
Meijers-Heijboer et al., 2001 [30] | * | * | ** | * | * | * | 7 | ||
Rebbeck et al., 2002 [31] | * | * | * | * | ** | * | * | * | 9 |
Rebbeck et al., 2004 [32] | * | * | * | * | ** | * | * | * | 9 |
Rutter et al., 2003 [33] | * | * | * | * | 4 | ||||
Skytte et al., 2011 [34] | * | * | * | * | ** | * | * | * | 9 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Liu, T.; Yu, J.; Gao, Y.; Ma, X.; Jiang, S.; Gu, Y.; Ming, W.-k. Prophylactic Interventions for Hereditary Breast and Ovarian Cancer Risks and Mortality in BRCA1/2 Carriers. Cancers 2024, 16, 103. https://doi.org/10.3390/cancers16010103
Liu T, Yu J, Gao Y, Ma X, Jiang S, Gu Y, Ming W-k. Prophylactic Interventions for Hereditary Breast and Ovarian Cancer Risks and Mortality in BRCA1/2 Carriers. Cancers. 2024; 16(1):103. https://doi.org/10.3390/cancers16010103
Chicago/Turabian StyleLiu, Taoran, Jing Yu, Yangyang Gao, Xinyang Ma, Shan Jiang, Yuanyuan Gu, and Wai-kit Ming. 2024. "Prophylactic Interventions for Hereditary Breast and Ovarian Cancer Risks and Mortality in BRCA1/2 Carriers" Cancers 16, no. 1: 103. https://doi.org/10.3390/cancers16010103
APA StyleLiu, T., Yu, J., Gao, Y., Ma, X., Jiang, S., Gu, Y., & Ming, W.-k. (2024). Prophylactic Interventions for Hereditary Breast and Ovarian Cancer Risks and Mortality in BRCA1/2 Carriers. Cancers, 16(1), 103. https://doi.org/10.3390/cancers16010103